Inventor · disambiguated record
Stephen Kaminsky
Also filed as: KAMINSKY STEPHEN · KAMINSKY STEPHEN M
19 granted patents·9 pending applications·54 citations·filing 2011–2025
93Inventor score
Files withTHERACLONE SCIENCES INC12UNIV CORNELL8CRYSTAL RONALD G3INT AIDS VACCINE INITIATIVE INC2BALLON DOUGLAS J1
Top patents by PatentIndex Score
28 records- 0196US12410243B2Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodiesINT AIDS VACCINE INITIATIVE INC·Filed 2023·Granted Sep 9, 2025·2 cites·16 claims
- 0296US10087239B2Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodyTHERACLONE SCIENCES INC·Filed 2016·Granted Oct 2, 2018·14 cites·7 claims
- 0395US9464131B2Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodyTHERACLONE SCIENCES INC·Filed 2013·Granted Oct 11, 2016·18 cites·4 claims
- 0491US12312396B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2024·Granted May 27, 2025·0 cites·32 claims
- 0591US11319362B2Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodiesTHERACLONE SCIENCES INC·Filed 2019·Granted May 3, 2022·3 cites·44 claims
- 0690US12122844B2Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodiesUNIV CORNELL·Filed 2020·Granted Oct 22, 2024·2 cites·14 claims
- 0786US12018067B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2023·Granted Jun 25, 2024·0 cites·29 claims
- 0885US10865234B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2019·Granted Dec 15, 2020·1 cites·7 claims
- 0983US10836811B2Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodyTHERACLONE SCIENCES INC·Filed 2017·Granted Nov 17, 2020·1 cites·4 claims
- 1081US10407493B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2019·Granted Sep 10, 2019·1 cites·20 claims
- 1181US9682133B2Disrupted adenovirus-based vaccine against drugs of abuseCRYSTAL RONALD G·Filed 2011·Granted Jun 20, 2017·9 cites·15 claims
- 1279US11845789B2Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodiesTHERACLONE SCIENCES INC·Filed 2021·Granted Dec 19, 2023·0 cites·15 claims
- 1378US2025320281A1Methods of treating hiv-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibodiesINT AIDS VACCINE INITIATIVE INC·Filed 2025·Application pending·0 cites
- 1476US11584789B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2020·Granted Feb 21, 2023·0 cites·31 claims
- 1574US12024568B2Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodiesCRYSTAL RONALD G·Filed 2013·Granted Jul 2, 2024·2 cites·10 claims
- 1674US10093947B2AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessationUNIV CORNELL·Filed 2013·Granted Oct 9, 2018·1 cites·12 claims
- 1769US10239934B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2018·Granted Mar 26, 2019·0 cites·14 claims
- 1860US9920111B2Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityTHERACLONE SCIENCES INC·Filed 2015·Granted Mar 20, 2018·0 cites·8 claims
- 1960US2025161483A1Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxiaLEXEO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2059US10004811B2Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addictionUNIV CORNELL·Filed 2013·Granted Jun 26, 2018·0 cites·13 claims
- 2158US2024307517A1Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addictionUNIV CORNELL·Filed 2022·Application pending·0 cites
- 2253US2023044351A1Apoe gene therapyUNIV CORNELL·Filed 2020·Application pending·0 cites
- 2350US2021381002A1Gene therapy for oxidative stressUNIV CORNELL·Filed 2019·Application pending·0 cites
- 2449US2022226502A1Adeno-associated virus vector delivery of cystathionine beta-synthase (cbs) enzyme for treating cbs deficiencyINSTITUTE FOR CANCER RES D/B/ATHE RES INSTITUTE OF FOX CHASE CANCER CENTER·Filed 2020·Application pending·0 cites
- 2543US12031144B2Oxidation-resistant AAT gene therapyUNIV CORNELL·Filed 2018·Granted Jul 9, 2024·0 cites·19 claims
- 2642US2013090375A1Virus-mediated delivery of bevacizumab for therapeutic applicationsCRYSTAL RONALD G·Filed 2012·Application pending·0 cites
- 2737US2015182638A1Virus-mediated delivery of bevacizumab for therapeutic applicationsUNIV CORNELL·Filed 2015·Application pending·0 cites
- 2837US2017067028A1Radiolabeling of adeno associated virusBALLON DOUGLAS J·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →